Oseltamivir Acid: Advanced Influenza Neuraminidase Inhibitor for Viral and Oncologic Research

Executive Summary: Oseltamivir acid, the active metabolite of the prodrug oseltamivir phosphate, is a potent and selective influenza neuraminidase inhibitor (https://www.apexbt.com/oseltamivir-acid.html). It blocks viral sialidase activity, halting the release of influenza virions from host cells and reducing disease propagation (Yang et al., 2025). Oseltamivir acid is highly soluble in DMSO (≥14.2 mg/mL), water with gentle warming (≥46.1 mg/mL), and ethanol with gentle warming (≥97 mg/mL), facilitating diverse experimental workflows. In vitro and in vivo studies show that Oseltamivir acid not only inhibits influenza virus replication but also impairs breast cancer cell viability and tumor metastasis in xenograft models. Resistance can develop, notably via the H275Y neuraminidase mutation in H1N1, underscoring the need for resistance monitoring and combinatorial research strategies.

Biological Rationale

Neuraminidase is an essential glycoprotein within the influenza virus envelope, facilitating the cleavage of terminal sialic acid (α-Neu5Ac) residues from host glycoproteins and glycolipids. This activity enables the efficient release of progeny virions following replication and prevents viral aggregation at the cell surface. Inhibiting neuraminidase with compounds such as Oseltamivir acid is a validated strategy for controlling influenza infection by blocking a critical step in the viral life cycle (Yang et al., 2025). The clinical success of prodrug approaches, in which oseltamivir phosphate is converted to oseltamivir acid by hepatic esterases, exemplifies the importance of carboxylesterase-mediated drug activation and the need for careful consideration of species differences in preclinical models. Furthermore, sialidase activity is implicated in the metastatic potential of certain cancers, such as breast cancer, where its inhibition may reduce tumor progression and dissemination.

Mechanism of Action of Oseltamivir acid

Oseltamivir acid acts as a competitive inhibitor of influenza virus neuraminidase (NA), binding to the enzyme's active site and preventing the cleavage of sialic acid residues. By blocking sialidase activity, it impedes the detachment and spread of nascent virions from the surface of infected host cells. The active metabolite is produced from the prodrug oseltamivir phosphate via carboxylesterase-mediated hydrolysis, primarily in the liver (Yang et al., 2025). The inhibition of NA suppresses viral propagation and reduces symptom severity. In cancer biology, the same sialidase-blocking mechanism can interfere with tumor cell motility and metastatic spread, as demonstrated in MDA-MB-231 and MCF-7 breast cancer cell lines and mouse xenograft models.

Evidence & Benchmarks

• Oseltamivir acid inhibits influenza neuraminidase activity in vitro with nanomolar potency, reducing viral replication and release from human respiratory epithelial cells (https://doi.org/10.1016/j.dmd.2025.100049).
• The conversion of oseltamivir phosphate to oseltamivir acid is catalyzed primarily by hepatic carboxylesterases, with species-specific differences in metabolic rate confirmed in humanized mice models (https://doi.org/10.1016/j.dmd.2025.100049).
• Oseltamivir acid is soluble in DMSO (≥14.2 mg/mL), water with gentle warming (≥46.1 mg/mL), and ethanol with gentle warming (≥97 mg/mL), supporting diverse laboratory protocols (https://www.apexbt.com/oseltamivir-acid.html).
• In vitro, oseltamivir acid reduces sialidase activity and cell viability in MDA-MB-231 and MCF-7 breast cancer cell lines in a dose-dependent manner (https://hemagglutinin-precursor.com/index.php?g=Wap&m=Article&a=detail&id=192).
• Combination of oseltamivir acid with chemotherapeutic agents (Cisplatin, 5-FU, Paclitaxel, Gemcitabine, Tamoxifen) enhances cytotoxicity in breast cancer models (https://influenza-a-virus-fragment.com/index.php?g=Wap&m=Article&a=detail&id=72).
• Intraperitoneal administration (30–50 mg/kg) in RAGxCγ double mutant mice bearing MDA-MB-231 xenografts results in significant inhibition of tumor vascularization, growth, and metastasis (https://hemagglutinin-precursor.com/index.php?g=Wap&m=Article&a=detail&id=192).
• The H275Y mutation in the neuraminidase gene confers resistance to oseltamivir acid in H1N1 strains, necessitating resistance screening in antiviral studies (https://doi.org/10.1016/j.dmd.2025.100049).

Applications, Limits & Misconceptions

Oseltamivir acid is widely used in research on influenza infection, viral sialidase activity assays, and anti-influenza drug development. Its demonstrated efficacy in breast cancer metastasis models extends its utility beyond classic virology. This article extends the analysis provided in "Oseltamivir Acid: Next-Generation Neuraminidase Inhibitor..." by quantifying solubility and resistance details, and clarifies workflow integration compared to "Oseltamivir Acid (SKU A3689): Reliable Solutions for Anti...", which focuses on experimental protocols. The present overview also updates translational perspectives discussed in "Oseltamivir Acid: Next-Generation Neuraminidase Inhibitor..." with recent resistance and prodrug metabolism insights.

Common Pitfalls or Misconceptions

• Oseltamivir acid is not active against non-influenza viruses; its mechanism is specific to influenza neuraminidase.
• Resistance can emerge rapidly in the presence of the H275Y neuraminidase mutation; routine resistance monitoring is essential.
• The compound is intended for research use only and is not approved for clinical or diagnostic applications.
• Long-term storage of oseltamivir acid solutions can lead to degradation; fresh solutions are recommended for each experiment (store powder at -20°C).
• Metabolic activation via carboxylesterases varies significantly across species; data from rodent models may not directly extrapolate to human pharmacokinetics.

Workflow Integration & Parameters

Oseltamivir acid (SKU A3689, APExBIO) is supplied as a solid, stable at -20°C. For in vitro work, solubilize in DMSO (≥14.2 mg/mL), water (≥46.1 mg/mL with gentle warming), or ethanol (≥97 mg/mL with gentle warming). Avoid repeated freeze-thaw cycles and long-term storage of solutions. For in vivo efficacy studies, doses of 30–50 mg/kg intraperitoneally have demonstrated robust antiviral and anti-metastatic activity in murine models. When using combination regimens with chemotherapeutics, titrate concentrations to assess additive or synergistic effects in cell viability and cytotoxicity assays. Employ validated sialidase activity assays to directly measure target engagement and downstream viral or tumor cell effects.

Conclusion & Outlook

Oseltamivir acid is a cornerstone neuraminidase inhibitor for influenza antiviral research and is increasingly recognized for its potential in cancer metastasis inhibition. Its well-characterized solubility, storage, and resistance parameters make it a robust tool for both fundamental and translational studies. Future research should focus on resistance management, detailed pharmacokinetic profiling in humanized models, and the exploration of combinatorial therapy strategies. For further information and ordering, consult the Oseltamivir acid product page at APExBIO.